Market Access News | pharmaphorum

News

NICE backs chemo-free CLL combination from AbbVie and Roche

Previously untreated patients with chronic lymphocytic leukaemia (CLL) in England will get a chemotherapy-free treatment option after NICE recommended NHS funding for a combination of AbbVi

News

FDA panel unimpressed with data for Alzheimer’s drug aducanu...

The FDA may have been minded to approve Biogen and Eisai’s Alzheimer’s candidate aducanumab, but its clinical advisors have little doubt that the evidence for the drug is lacking.<

News

After two decades, NICE begins consultation on drug assessme...

The UK’s drug cost-effectiveness body NICE has launched a public consultation, presenting the case for change about how it assesses medicines, medical devices and diagnostics.

News

Pharma may avoid worst-case drug pricing scenario as US elec...

Pharma may have avoided a worst case scenario amid the political upheavals in the US elections with the threat of tough drug price legislation lowered, with hawkish Democrats unlikely to wi

News

Trials and tribulations in Biogen's Alzheimer’s drug reviews

Regulatory reviews of Biogen’s Alzheimer’s drug aducanumab are now ongoing on both sides of the Atlantic, but debate is still ongoing about whether the data behind the drug is strong enough

News